Detalhe da pesquisa
1.
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma.
Hematol Oncol
; 42(1): e3236, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932900
2.
Nutritional counseling improves mortality and prevents hepatic encephalopathy in patients with alcohol-associated liver disease.
Hepatol Res
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38683882
3.
A case of A20 haploinsufficiency complicated by autoimmune hepatitis.
Hepatol Res
; 54(6): 606-611, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126665
4.
Impact of body fat accumulation on metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults.
Hepatol Res
; 53(8): 691-700, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37143429
5.
Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
Hepatol Res
; 53(3): 238-246, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433862
6.
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease.
Hepatol Res
; 52(11): 928-936, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35861232
7.
Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy.
Hepatol Res
; 51(6): 662-673, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242359
8.
Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis.
Hepatol Res
; 49(1): 82-95, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30156741
9.
[Liver cirrhosis and sarcopenia].
Nihon Shokakibyo Gakkai Zasshi
; 120(9): 709-716, 2023.
Artigo
em Japonês
| MEDLINE | ID: mdl-37690826
10.
Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not.
Cancers (Basel)
; 16(2)2024 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38275883
11.
Short-latency reaction time and accuracy are impaired in patients with cirrhosis: An international multicenter retrospective study.
Geriatr Gerontol Int
; 24(1): 25-31, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37973613
12.
A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
J Gastroenterol
; 59(1): 45-55, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37843553
13.
Dysphagia risk evaluated by the Eating Assessment Tool-10 is associated with health-related quality of life in patients with chronic liver disease.
Nutrition
; 124: 112440, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652977
14.
Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults.
Sci Rep
; 14(1): 2194, 2024 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38273030
15.
Animal naming test stratifies the risk of falls and fall-related fractures in patients with cirrhosis.
Sci Rep
; 14(1): 4307, 2024 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38383771
16.
Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
J Clin Med
; 13(4)2024 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38398471
17.
A Case of Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab.
Intern Med
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38432964
18.
Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease.
J Clin Med
; 12(8)2023 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37109203
19.
Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis.
JGH Open
; 7(3): 208-214, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36968562
20.
Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates.
Cancers (Basel)
; 15(17)2023 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686497